HUP0001698A2 - Substituted pyrimidine compounds and their use - Google Patents
Substituted pyrimidine compounds and their useInfo
- Publication number
- HUP0001698A2 HUP0001698A2 HU0001698A HUP0001698A HUP0001698A2 HU P0001698 A2 HUP0001698 A2 HU P0001698A2 HU 0001698 A HU0001698 A HU 0001698A HU P0001698 A HUP0001698 A HU P0001698A HU P0001698 A2 HUP0001698 A2 HU P0001698A2
- Authority
- HU
- Hungary
- Prior art keywords
- groups
- hiv
- substituents
- disease
- diseases
- Prior art date
Links
- 150000003230 pyrimidines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 abstract 2
- 241000701022 Cytomegalovirus Species 0.000 abstract 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 abstract 2
- 206010040070 Septic Shock Diseases 0.000 abstract 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 abstract 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010002198 Anaphylactic reaction Diseases 0.000 abstract 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 206010006895 Cachexia Diseases 0.000 abstract 1
- 206010063094 Cerebral malaria Diseases 0.000 abstract 1
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 1
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- 206010012442 Dermatitis contact Diseases 0.000 abstract 1
- 201000005569 Gout Diseases 0.000 abstract 1
- 208000031886 HIV Infections Diseases 0.000 abstract 1
- 206010020164 HIV infection CDC Group III Diseases 0.000 abstract 1
- 208000007514 Herpes zoster Diseases 0.000 abstract 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 abstract 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 208000034578 Multiple myelomas Diseases 0.000 abstract 1
- 206010028289 Muscle atrophy Diseases 0.000 abstract 1
- 208000000112 Myalgia Diseases 0.000 abstract 1
- 208000010191 Osteitis Deformans Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 208000027868 Paget disease Diseases 0.000 abstract 1
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 206010037660 Pyrexia Diseases 0.000 abstract 1
- 208000033464 Reiter syndrome Diseases 0.000 abstract 1
- 206010063837 Reperfusion injury Diseases 0.000 abstract 1
- 206010040047 Sepsis Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 206010044248 Toxic shock syndrome Diseases 0.000 abstract 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 abstract 1
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
- 206010046851 Uveitis Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 230000036783 anaphylactic response Effects 0.000 abstract 1
- 208000003455 anaphylaxis Diseases 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 210000001185 bone marrow Anatomy 0.000 abstract 1
- 208000019664 bone resorption disease Diseases 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 208000010247 contact dermatitis Diseases 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 206010022000 influenza Diseases 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 208000027202 mammary Paget disease Diseases 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 230000020763 muscle atrophy Effects 0.000 abstract 1
- 208000013465 muscle pain Diseases 0.000 abstract 1
- 201000000585 muscular atrophy Diseases 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 210000000496 pancreas Anatomy 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 208000002574 reactive arthritis Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000036303 septic shock Effects 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- 238000002054 transplantation Methods 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
- 241000701161 unidentified adenovirus Species 0.000 abstract 1
- 241001529453 unidentified herpesvirus Species 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
- C07D213/643—2-Phenoxypyridines; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
A találmány tárgyát az (I) általános képletű vegyületek vagy ezekgyógyászatilag megfelelő sói, valamint e vegyületeket tartalmazógyógyászati készítmények képezik. A találmány szerinti vegyületekeredményesen alkalmazhatók számos betegség kezelésére vagymegelőzésére, mint a gyulladásos betegségek, így reumaszerű ízületigyulladás, Paget-kór, oszteoporózis, myeloma multiplex, uveagyulladás,akut vagy krónikus csontvelő-leukémia, hasnyálmirigy b-sejtekpusztulása, csontízületi gyulladás, a reumaszerű csigolyagyulladás,köszvényes ízület igyulladás, gyulladásos bélbetegségek, felnőttkorilégzésnehézség tünetegyüttese (ARDS), psoriasis, Crohn-féle kór,szénanátha, fekélyes vastagbélgyulladás, anaphylaxis, érintkezésselterjedő bőrgyulladás, asztma, izomsorvadás, cachexia, Reiter-féletünetegyüttes, I. típusú diabétesz, II. típusú diabétesz,csontreszorpciós betegségek, átültetésnél fellépő születési reakciók,Alzheimer-kór, szélütés, szívizominfarktus, ischémiás reperfúzióssérülés, atherosclerosis, agyi traumák, sclerosis multiplex, agyimalária, szepszis, szeptikus sokk, toxikus sokk tünetegyüttese, láz, aHIV-1, HIV-2, HIV-3, citomegalovírus (CMV), influenza, adenovírus,herpeszvírus vagy herpesz zoster fertőzések nyomán fellépőizomfájdalom. Az (I) általános képletben a szubsztituensek jelentéseigen sokféle, így R1 és R2 jelentése egymástól függeltenül -Z-Y, ahol Z jelentése egy vegyértékkötés, alkil-, alkenil-, alkinil-,heterociklusos csoport, aril- vagy heteroarilcsoport, amely csoportokmindegyike igen sokféle szubsztituenst hordozhat; Y többek között hidrogénatom, halogénatom vagy nitrocsoport, -C(O)-R20vagy -C(NR5)-NR5R21 általános képletű csoport, -OR21, -O-C(O)-R21 vagy-O-C(O)-NR5R21 vagy -O-C(O)-NR22-S(O)2-R20 általános képletű csoport; R11 és R12 jelentése adott esetben szubsztituált aril- vagyheteroarilcsoport. A fenti csoportokban szereplő R5, R20, R21 és R22csoportok igen sokféle szubsztituenst jelenthetnek. ÓThe subject of the invention is the compounds of general formula (I) or their pharmaceutically acceptable salts, as well as pharmaceutical preparations containing these compounds. The compounds according to the invention can be effectively used for the treatment or prevention of many diseases, such as inflammatory diseases, such as rheumatoid arthritis, Paget's disease, osteoporosis, multiple myeloma, uveitis, acute or chronic bone marrow leukemia, b-cell destruction of the pancreas, osteoarthritis, rheumatoid spondylitis, gout arthritis, inflammatory bowel diseases, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, hay fever, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle atrophy, cachexia, Reiter's syndrome, type I diabetes, II. type 2 diabetes, bone resorption diseases, birth reactions occurring during transplantation, Alzheimer's disease, stroke, myocardial infarction, ischemic reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, HIV-1, HIV-2 , HIV-3, cytomegalovirus (CMV), influenza, adenovirus, herpes virus or herpes zoster infections, muscle pain. The meanings of the substituents in the general formula (I) are very diverse, so that R1 and R2 independently mean -Z-Y, where Z means a valence bond, alkyl-, alkenyl-, alkynyl-, heterocyclic group, aryl or heteroaryl group, each of which groups can carry a wide variety of substituents ; Y includes hydrogen, halogen or nitro, -C(O)-R20 or -C(NR5)-NR5R21, -OR21, -O-C(O)-R21 or -O-C(O)-NR5R21 or -O-C(O )-NR22-S(O)2-R20 group; R11 and R12 are optionally substituted aryl or heteroaryl groups. The R5, R20, R21 and R22 groups in the above groups can represent a wide variety of substituents. HE
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3212896P | 1996-12-05 | 1996-12-05 | |
US5095097P | 1997-06-13 | 1997-06-13 | |
US97605497A | 1997-11-21 | 1997-11-21 | |
PCT/US1997/022390 WO1998024782A2 (en) | 1996-12-05 | 1997-12-04 | Substituted pyrimidine compounds and their use |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0001698A2 true HUP0001698A2 (en) | 2001-04-28 |
HUP0001698A3 HUP0001698A3 (en) | 2002-07-29 |
Family
ID=27364030
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0001698A HUP0001698A3 (en) | 1996-12-05 | 1997-12-04 | Substituted pyrimidine compounds and their use |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP0948497A2 (en) |
CN (1) | CN1246858A (en) |
AR (1) | AR048564A1 (en) |
AU (1) | AU733877C (en) |
BG (1) | BG65128B1 (en) |
BR (1) | BR9713850A (en) |
CA (1) | CA2274063C (en) |
CZ (1) | CZ296911B6 (en) |
HU (1) | HUP0001698A3 (en) |
IL (1) | IL130180A0 (en) |
NZ (1) | NZ335997A (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7427615B2 (en) | 2001-09-21 | 2008-09-23 | Mitsubishi Pharma Corporation | 3-substituted-4-pyrimidone derivatives |
US7504411B2 (en) | 2003-03-26 | 2009-03-17 | Mitsubishi Tanabe Pharma Corporation | 2,3,6-Trisubstituted-4-pyrimidone derivatives |
US7572793B2 (en) | 2001-09-21 | 2009-08-11 | Mitsubishi Tanabe Pharma Corporation | 3-Substituted-4-pyrimidone derivatives |
US7683069B2 (en) | 2002-12-16 | 2010-03-23 | Mitsubishi Tanabe Pharma Corporation | 3-substituted-4-pyrimidone derivatives |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2001295026B2 (en) * | 2000-09-06 | 2008-04-03 | Novartis Vaccines And Diagnostics, Inc. | Inhibitors of glycogen synthase kinase 3 |
TWI330183B (en) * | 2001-10-22 | 2010-09-11 | Eisai R&D Man Co Ltd | |
EP1340759A1 (en) * | 2002-02-28 | 2003-09-03 | Sanofi-Synthelabo | 1-[alkyl], 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7-(pyrimidin-4-yl)-imidazo[1,2-a]pyrimidin-5(1H)-one derivatives |
PT2629776T (en) * | 2010-10-18 | 2017-11-15 | Cerenis Therapeutics Holding Sa | Compounds, compositions and methods useful for cholesterol mobilisation |
TWI651310B (en) * | 2014-02-20 | 2019-02-21 | 日商日本煙草產業股份有限公司 | Triterpenoids and their medical use |
CA3002632C (en) * | 2015-10-29 | 2023-08-29 | Aska Pharmaceutical Co., Ltd. | Pyrimidine derivative |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE759176A (en) * | 1969-11-20 | 1971-05-19 | Sandoz Sa | PYRIMIDINE DERIVATIVES, THEIR PREPARATION AND MEDICINAL PRODUCTS CONTAINING THESE DERIVES |
US4438117A (en) * | 1980-09-03 | 1984-03-20 | E. I. Du Pont De Nemours And Company | 2-Substituted thio-4,5-diarylpyrimidines |
DE3319843A1 (en) * | 1983-06-01 | 1984-12-06 | Ali-Akbar Dipl.-Chem. Dr. 4300 Mülheim Pourzal | Process for the preparation of pyrimidines from nitrile and alkynes |
US4500533A (en) * | 1983-06-22 | 1985-02-19 | Eli Lilly And Company | 2,4,5-Triaryl pyrimidines and a method of treating pain, fever, thrombosis, inflammation and arthritis |
US5077142A (en) * | 1989-04-20 | 1991-12-31 | Ricoh Company, Ltd. | Electroluminescent devices |
US5620999A (en) * | 1994-07-28 | 1997-04-15 | Weier; Richard M. | Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation |
-
1997
- 1997-12-04 CN CN97181563A patent/CN1246858A/en active Pending
- 1997-12-04 AR ARP970105689A patent/AR048564A1/en not_active Application Discontinuation
- 1997-12-04 IL IL13018097A patent/IL130180A0/en unknown
- 1997-12-04 NZ NZ335997A patent/NZ335997A/en unknown
- 1997-12-04 BR BR9713850-9A patent/BR9713850A/en not_active Application Discontinuation
- 1997-12-04 HU HU0001698A patent/HUP0001698A3/en unknown
- 1997-12-04 AU AU60120/98A patent/AU733877C/en not_active Ceased
- 1997-12-04 CA CA002274063A patent/CA2274063C/en not_active Expired - Fee Related
- 1997-12-04 CZ CZ0201599A patent/CZ296911B6/en not_active IP Right Cessation
- 1997-12-04 EP EP97954778A patent/EP0948497A2/en not_active Withdrawn
-
1999
- 1999-06-22 BG BG103512A patent/BG65128B1/en unknown
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7427615B2 (en) | 2001-09-21 | 2008-09-23 | Mitsubishi Pharma Corporation | 3-substituted-4-pyrimidone derivatives |
US7572793B2 (en) | 2001-09-21 | 2009-08-11 | Mitsubishi Tanabe Pharma Corporation | 3-Substituted-4-pyrimidone derivatives |
US7683069B2 (en) | 2002-12-16 | 2010-03-23 | Mitsubishi Tanabe Pharma Corporation | 3-substituted-4-pyrimidone derivatives |
US7504411B2 (en) | 2003-03-26 | 2009-03-17 | Mitsubishi Tanabe Pharma Corporation | 2,3,6-Trisubstituted-4-pyrimidone derivatives |
Also Published As
Publication number | Publication date |
---|---|
BG103512A (en) | 2000-07-31 |
IL130180A0 (en) | 2000-06-01 |
BR9713850A (en) | 2000-02-29 |
AU733877C (en) | 2003-05-08 |
AU733877B2 (en) | 2001-05-31 |
AU6012098A (en) | 1998-06-29 |
CA2274063A1 (en) | 1998-06-11 |
EP0948497A2 (en) | 1999-10-13 |
CN1246858A (en) | 2000-03-08 |
CZ9902015A3 (en) | 1999-11-17 |
HUP0001698A3 (en) | 2002-07-29 |
CZ296911B6 (en) | 2006-07-12 |
BG65128B1 (en) | 2007-03-30 |
AR048564A1 (en) | 2006-05-10 |
CA2274063C (en) | 2007-09-04 |
NZ335997A (en) | 2001-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0101099A2 (en) | Substituted pyridine and pyridazine compounds and their pharmaceutical use | |
Van Aerschot et al. | 3'-Fluoro-2', 3'-dideoxy-5-chlorouridine: most selective anti-HIV-1 agent among a series of new 2'-and 3'-fluorinated 2', 3'-dideoxynucleoside analogs | |
KR102030305B1 (en) | Indole carboxamide compounds useful as kinase inhibitors | |
EP0392791B1 (en) | Antiviral compounds | |
HUP0001698A2 (en) | Substituted pyrimidine compounds and their use | |
KR100589935B1 (en) | Novel Pyrazine Derivatives or Salts Thereof, and Pharmaceutical Composition Containing the Same | |
Tanaka et al. | Synthesis and antiviral activity of deoxy analogs of 1-[(2-hydroxyethoxy) methyl]-6-(phenylthio) thymine (HEPT) as potent and selective anti-HIV-1 agents | |
IL123330A (en) | Nucleosides having 2'-ether group their preparation their use in the production of oligonucleotides and pharmaceutical compositions containing them | |
DK0481214T3 (en) | Prophylactic drugs of phosphonates | |
ZA921804B (en) | Cyclic urea derivatives, pharmaceutical compositions containing these compounds and processes for preparing them. | |
AR039842A1 (en) | REPLACED HETEROCICLICAL COMPOUNDS AND EMPLOYMENT METHODS | |
PE20060837A1 (en) | 3H-OXAZOLE AND 3H-THIAZOLE [4,5-d] PYRIMIDIN-2-ONA 3,5-DISUSTITUIDE AND 3,5,7-TRISUSTITUIDE COMPOUNDS AND PROPHARMACES OF THE SAME | |
IL84810A (en) | Pharmaceutical antiviral compositions containing 1-beta-d-arabinofuranosyl-5-(1-alkynyl)cytosine and uracil derivatives thereof,some new such compounds and their preparation | |
JP2002506878A5 (en) | ||
JP2002526501A5 (en) | ||
WO2002069903A3 (en) | Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases | |
JP2683297B2 (en) | Pyrimidine acyclonucleoside derivative | |
MY141472A (en) | Substituted phenyl phenol leukotriene antagonists | |
AU7320100A (en) | Hydroxamic acid derivatives, process for the production thereof and drugs containing the same as the active ingredient | |
Goudgaon et al. | 1-(Ethoxymethyl)-6-(phenylselenenyl) pyrimidines with activity against human immunodeficiency virus types 1 and 2 | |
FI92491B (en) | Process for the preparation of pharmacologically active nucleoside derivatives | |
HUP0101230A2 (en) | Chemical process for the production of sulphinyl derivatives by oxidation of the corresponding co-derivatives with perborates | |
ATE393157T1 (en) | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF APPLICATION | |
JP4076114B2 (en) | 4'-C-ethynylpurine nucleoside compounds | |
DE60312342D1 (en) | 1,4,5-SUBSTITUTED 1,2-DIHYDRO-PYRAZOL-3-ONE AND 3-ALKOXY-1H-PYRAZOLE DERIVATIVES AS TNF-ALPHA AND INTERLEUKIN-SUBSTANCING ACTIVITIES FOR THE TREATMENT OF INFLAMMATION |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |